Expert Review of Clinical Immunology最新文献_第7页

The multidisciplinary approach to diagnosing inborn errors of immunity: a comprehensive review of discipline-based manifestations. 诊断先天性免疫错误的多学科方法：基于学科表现的全面回顾。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-10-01 Epub Date: 2024-07-02 DOI: 10.1080/1744666X.2024.2372335

Niloufar Yazdanpanah, Nima Rezaei

{"title":"The multidisciplinary approach to diagnosing inborn errors of immunity: a comprehensive review of discipline-based manifestations.","authors":"Niloufar Yazdanpanah, Nima Rezaei","doi":"10.1080/1744666X.2024.2372335","DOIUrl":"10.1080/1744666X.2024.2372335","url":null,"abstract":"Introduction: Congenital immunodeficiency is named primary immunodeficiency (PID), and more recently inborn errors of immunity (IEI). There are more than 485 conditions classified as IEI, with a wide spectrum of clinical and laboratory manifestations.Areas covered: Regardless of the developing knowledge of IEI, many physicians do not think of IEI when approaching the patient's complaint, which leads to delayed diagnosis, misdiagnosis, serious infectious and noninfectious complications, permanent end-organ damage, and even death. Due to the various manifestations of IEI and the wide spectrum of associated conditions, patients refer to specialists in different disciplines of medicine and undergo - mainly symptomatic - treatments, and because IEI are not included in physicians' differential diagnosis, the main disease remains undiagnosed.Expert opinion: A multidisciplinary approach may be a proper solution. Manifestations and the importance of a multidisciplinary approach in the diagnosis of main groups of IEI are discussed in this article.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1237-1259"},"PeriodicalIF":3.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141440379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of histone deacetylases in inflammatory respiratory diseases: an update. 组蛋白去乙酰化酶在呼吸系统炎症性疾病中的作用：最新进展。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-10-01 Epub Date: 2024-06-04 DOI: 10.1080/1744666X.2024.2363803

Sicen Pan, Xiangdong Wang, Jian Jiao, Luo Zhang

{"title":"The role of histone deacetylases in inflammatory respiratory diseases: an update.","authors":"Sicen Pan, Xiangdong Wang, Jian Jiao, Luo Zhang","doi":"10.1080/1744666X.2024.2363803","DOIUrl":"10.1080/1744666X.2024.2363803","url":null,"abstract":"Introduction: Histone deacetylases (HDACs) catalyze the removal of acetyl groups from lysine residues of histones and other proteins, generally leading to a closed chromosomal configuration and transcriptional repression. Different HDACs have distinct substrate specificities and functions in different biological processes. Accumulating evidence indicates that HDACs play a key role in the pathogenesis of multiple respiratory diseases.Areas covered: After an extensive search of the PubMed database, Web of Science and ClinicalTrials.gov, covering the period from 1992 to 2024, this review summarizes recent advances in understanding the role of HDACs in inflammatory respiratory diseases, including allergic rhinitis (AR), chronic rhinosinusitis (CRS), asthma and chronic obstructive pulmonary disease (COPD). We also examine recent progress on the efficacy and potential use of histone deacetylase inhibitors (HDACi) for the treatment of these diseases.Expert opinion: Available data indicate that HDACs play an important role in the development of common inflammatory respiratory diseases, and HDACi have shown promise as treatments for these diseases. However, the exact roles and underlying mechanisms of specific HDACs in disease pathogenesis require further study. Additional work is necessary to develop novel potent HDACi with high isoform selectivity.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1193-1203"},"PeriodicalIF":3.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141186304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Changes in health-related quality of life in common variable immunodeficiency: an eight-year journey, including the COVID-19 pandemic. 常见变异性免疫缺陷症患者与健康相关的生活质量变化：八年历程，包括 COVID-19 大流行。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-10-01 Epub Date: 2024-07-12 DOI: 10.1080/1744666X.2024.2368195

Federica Pulvirenti, Annalisa Villa, Matteo D'Ambrosi, Gabriella Cusa, Patricia Quijada-Morales, Eduardo de la Fuente-Munoz, Maddalena Sciannamea, Giulia Garzi, Isabella Quinti

{"title":"Changes in health-related quality of life in common variable immunodeficiency: an eight-year journey, including the COVID-19 pandemic.","authors":"Federica Pulvirenti, Annalisa Villa, Matteo D'Ambrosi, Gabriella Cusa, Patricia Quijada-Morales, Eduardo de la Fuente-Munoz, Maddalena Sciannamea, Giulia Garzi, Isabella Quinti","doi":"10.1080/1744666X.2024.2368195","DOIUrl":"10.1080/1744666X.2024.2368195","url":null,"abstract":"Background: Personalized medicine requires the assessment of the impact of health care interventions on Health-Related Quality of Life.Research design and methods: We run an observational study of HRQoL in 140 CVID patients with biannual assessments over 8 years using a disease-specific tool, the CVID_QoL, and the GHQ questionnaires. Factors influencing changes in HRQoL scores were identified using multiple linear regression models with a stepwise procedure.Results: Infections frequency, female gender, and chronic enteropathy were associated with worse global CVID_QoL scores. The presence of permanent organ damage and older age contributed to the perception of being at risk of health deterioration, while chronic enteropathy was associated with fatigue. The presence of permanent organ damage was also associated with perceived difficulties in usual activities. The frequency of infections was the main risk factor for difficulties in long-term planning and perceptions of vulnerability. Before COVID-19, improved HRQoL scores were associated with reduced respiratory infections and changes in immunoglobulin replacement route and setting. The COVID-19 pandemic caused a sudden deterioration in all HRQoL dimensions, and a further deterioration in the emotional dimension was observed during the pandemic period. Patients who died during the study had worse CVID_QoL scores at all time points, confirming that HRQoL performance is strongly related to patient outcome.Conclusions: Periodic HRQoL assessments are needed to capture relevant issues that change over time in patients affected by long-term chronic conditions such CVID, possibly identifying areas of intervention.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1269-1280"},"PeriodicalIF":3.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141589972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunological alterations in the endothelial barrier: a new predictive and therapeutic paradigm for sepsis. 内皮屏障的免疫学改变：脓毒症的新预测和治疗范例。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-10-01 Epub Date: 2024-06-11 DOI: 10.1080/1744666X.2024.2366301

Jun Feng, Lina Liu, Junya Liu, Junshuai Wang

{"title":"Immunological alterations in the endothelial barrier: a new predictive and therapeutic paradigm for sepsis.","authors":"Jun Feng, Lina Liu, Junya Liu, Junshuai Wang","doi":"10.1080/1744666X.2024.2366301","DOIUrl":"10.1080/1744666X.2024.2366301","url":null,"abstract":"Introduction: Despite the fact incidence and mortality vary widely among regions, sepsis remains a major cause of morbidity and cost worldwide. The importance of the endothelial barrier in sepsis and infectious diseases is increasingly recognized; however, the underlying pathophysiology of the endothelial barrier in sepsis remains poorly understood.Areas covered: Here we review the advances in basic and clinical research for relevant papers in PubMed database. We attempt to provide an updated overview of immunological alterations in endothelial dysfunction, discussing the central role of endothelial barrier involved in sepsis to provide new predictive and therapeutic paradigm for sepsis.Expert opinion: Given its physiological and immunological functions in infectious diseases, the endothelial barrier has been dramatically altered in sepsis, suggesting that endothelial dysfunction may play a critical role in the pathogenesis of sepsis. Although many reliable biomarkers have been investigated to monitor endothelial activation and injury in an attempt to find diagnostic and therapeutic tools, there are no specific therapies to treat sepsis due to its complex pathophysiology. Since sepsis is initiated by both hyperinflammation and immunoparalysis occurring simultaneously, a 'one-treatment-fits-all' strategy for sepsis-induced immune injury and immunoparalysis is bound to fail, and an individualized 'precision medicine' approach is required.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1205-1217"},"PeriodicalIF":3.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141287971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Harnessing the power of AI-based models to accelerate drug discovery against immune diseases. 利用人工智能模型的力量，加快针对免疫疾病的药物研发。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-10-01 Epub Date: 2024-07-01 DOI: 10.1080/1744666X.2024.2373915

Philippe Moingeon

引用次数: 0

Treatment intensification in Kawasaki disease - current perspectives. 川崎病的强化治疗--当前视角。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-10-01 Epub Date: 2024-07-15 DOI: 10.1080/1744666X.2024.2378900

Prabal Barman, Rakesh Kumar Pilania, Gayathri Cv, Abarna Thangaraj, Munish Arora, Surjit Singh

{"title":"Treatment intensification in Kawasaki disease - current perspectives.","authors":"Prabal Barman, Rakesh Kumar Pilania, Gayathri Cv, Abarna Thangaraj, Munish Arora, Surjit Singh","doi":"10.1080/1744666X.2024.2378900","DOIUrl":"10.1080/1744666X.2024.2378900","url":null,"abstract":"Introduction: Intravenous immunoglobulin is the standard of care in Kawasaki disease. However, a subset of patients exhibits resistance to intravenous immunoglobulin treatment, even when Kawasaki disease is promptly diagnosed and managed. While intravenous immunoglobulin reduces the occurrence of coronary artery abnormalities from 15-25% to 3-5%, it does not entirely eliminate the risk. Besides, management guidelines for non-coronary complications of Kawasaki disease, for instance, myocarditis, remain speculative.Areas covered: Recent literature suggests that a subset of patients with Kawasaki disease may benefit from treatment intensification with drugs, such as corticosteroids, infliximab, anakinra, and/or ciclosporin. In this manuscript, we have reviewed recent advances in the management of Kawasaki disease, especially with regard to preemptive intensification of therapy in children at high risk of cardiac complications. A comprehensive search was made using Web of Science, Scopus, and PubMed databases to gather English articles published from 1967 to 2023 on the treatment of Kawasaki disease. We incorporated the following words in the search strategy: 'Kawasaki disease,' 'intravenous immunoglobulin/IVIg,' 'intravenous immunoglobulin/IVIg-resistant Kawasaki disease,' 'treatment intensification,' or 'primary intensification of treatment/therapy.'Expert opinion: The 'high-risk' group in Kawasaki disease needs to be identified with early intensification of primary therapy for better coronary and myocardial outcomes.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1179-1191"},"PeriodicalIF":3.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141558437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The effect of intense pulsed light combined with topical 0.05% Cyclosporin A eyedrops in the treatment of Sjögren's syndrome related dry eye. 强脉冲光与 0.05% 环孢素 a 外用眼药水联合治疗与斯约格伦综合征有关的干眼症的效果。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-10-01 Epub Date: 2024-05-27 DOI: 10.1080/1744666X.2024.2358157

Yanan Huo, Xiaodan Huang, Lin Lin, Shuo Yang, Zhenwei Qin, Zhu Yirui, Yujie Mou, Xiuming Jin

{"title":"The effect of intense pulsed light combined with topical 0.05% Cyclosporin A eyedrops in the treatment of Sjögren's syndrome related dry eye.","authors":"Yanan Huo, Xiaodan Huang, Lin Lin, Shuo Yang, Zhenwei Qin, Zhu Yirui, Yujie Mou, Xiuming Jin","doi":"10.1080/1744666X.2024.2358157","DOIUrl":"10.1080/1744666X.2024.2358157","url":null,"abstract":"Objectives: This study aimed to assess the effectiveness and safety of intense pulsed light (IPL) therapy plus topical 0.05% cyclosporine A (CsA) eye drops to treat Sjögren's Syndrome-related dry eyes (SS-DE).Research design and methods: In this prospective, randomized trial included, 60 individuals with SS-DE symptoms were randomized to receive topical eye drops containing either 0.1% sodium hyaluronate (Group S) or 0.05% CsA (Group C) plus IPL therapy. Before the first treatment (baseline), and at 12, 16, and 20 weeks after treatment commencement, we assessed the best corrected visual acuity (BCVA), the Ocular Surface Disease Index (OSDI) score, the Schirmer I test (SIT), noninvasive tear breakup time (NBUT), corneal fluorescein staining (CFS), meibomian gland (MG) dropout, lid margin abnormality, MG expressibility, and meibum quality.Results: Both groups showed significant improvements in the OSDI, NBUT, CFS, MG expressibility, and meibum quality (all p < 0.05). Group C showed a greater increase in OSDI, NBUT, MG expressibility, and meibum quality (all p < 0.05). Moreover, SIT and lid margin abnormalities significantly improved in Group C (both p < 0.05), but not in Group S.Conclusion: Treatment with 0.05% CsA eyedrops plus IPL therapy could significantly reduce the issues and physical discomfort of patients with SS-DE.Clinical trial: Registered on 20 July 2021, with the registration number ChiCTR2100049059.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1261-1267"},"PeriodicalIF":3.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141087467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Salivary gland biopsy as a prognostic tool in Sjögren's syndrome. 唾液腺活检作为斯约格伦综合征的预后工具。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-10-01 Epub Date: 2024-06-24 DOI: 10.1080/1744666X.2024.2368189

Roberto Dal Pozzolo, Giacomo Cafaro, Carlo Perricone, Santina Calvacchi, Lorenza Bruno, Anna Colangelo, Francesco Tromby, Roberto Gerli, Elena Bartoloni

{"title":"Salivary gland biopsy as a prognostic tool in Sjögren's syndrome.","authors":"Roberto Dal Pozzolo, Giacomo Cafaro, Carlo Perricone, Santina Calvacchi, Lorenza Bruno, Anna Colangelo, Francesco Tromby, Roberto Gerli, Elena Bartoloni","doi":"10.1080/1744666X.2024.2368189","DOIUrl":"10.1080/1744666X.2024.2368189","url":null,"abstract":"Introduction: Primary Sjögren's syndrome (pSS) is an autoimmune disorder primarily affecting salivary and lacrimal glands, although about 40% of patients experience systemic complications. In this setting, the identification of patient phenotypes characterized by increased risk of extra-glandular involvement still represents an unmet need.Areas covered: The aim of this paper is to review the scientific evidence on the utility of salivary gland biopsies in pSS, emphasizing their role in defining prognosis. In latest years, research focused on disease-specific clinical, serological, or histological features able to categorize patient prognosis. Among histopathological features, focus score and ectopic germinal centers exhibit associations with glandular and extraglandular manifestations, including higher rates of lymphomagenesis.Expert opinion: Pathological characterization of salivary glands provides information that go beyond a mere diagnostic or classification utility, providing insights for a stratification of disease severity and for predicting systemic manifestations. Thus, a salivary gland biopsy should be offered to all patients and included in routine practice, even when not strictly required for diagnostic purposes. More advanced analysis techniques of the tissue, including immunohistochemistry and 'omics' should be further explored in longitudinal studies to boost the ability to further stratify and predict disease evolution.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1139-1147"},"PeriodicalIF":3.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnostic accuracy of QuantiFERON-TB Gold Plus with Chemiluminescence Immunoassay: a systematic review and meta-analysis QuantiFERON-TB Gold Plus化学发光免疫测定的诊断准确性：系统综述和荟萃分析

IF 4.4 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-09-19 DOI: 10.1080/1744666x.2024.2407550

Shima Mahmoudi, Seyed Mohammad Sajad Hosseini Sharif

引用次数: 0

Complement as a major mediator of ANCA vasculitis and a target for precision therapy 补体是 ANCA 血管炎的主要介质和精准治疗的靶点

IF 4.4 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-09-18 DOI: 10.1080/1744666x.2024.2405170

Donna O. Bunch, Sarah E. Lewis, Hong Xiao, Peiqi Hu, J. Charles Jennette, Eveline Y. Wu

引用次数: 0